Key Stats for Gilead Sciences Stock
- 52-Week Range: $93 to $157
- Current Price: $136
- Street Mean Target: $158
- Street High Target: $180
- TIKR Model Target (Dec. 2030): $164
What Happened?
Gilead Sciences stock (GILD) represents one of the more compelling re-rating setups in large-cap biotech: a company best known for dominating HIV treatment that has quietly deployed more than $16 billion in acquisitions since February 2026 while still growing its base business at mid-single-digit rates.
In February, Gilead agreed to acquire Arcellx for up to $7.8 billion, taking full ownership of anito-cel, a BCMA CAR-T therapy for relapsed and refractory multiple myeloma that posted 96% overall response and 74% complete response in Phase II.
In March, Gilead agreed to acquire Ouro Medicines for $1.68 billion upfront plus up to $500 million in milestones, adding gamgertamig, a T-cell engager targeting B and plasma cells across more than 20 autoimmune disease indications, with co-development costs split equally with Galapagos.
In April, Gilead announced the acquisition of Tubulis GmbH for $3.15 billion upfront plus up to $1.85 billion in milestone payments, bringing a next-generation antibody-drug conjugate platform and lead asset TUB-040, which showed a 50% confirmed overall response in 46 patients with platinum-resistant ovarian cancer and zero treatment discontinuations.
These acquisitions arrived as the existing commercial engine was already running hard: full year 2025 HIV sales reached $20.8 billion, up 6% year over year, with Biktarvy at $14.3 billion and the HIV prevention franchise growing 47%, driven by Yeztugo, the twice-yearly injectable that achieved 90% payer coverage in under six months.
CEO Daniel O’Day told investors in Q4 2025 earnings call: “With no major LOEs until 2036 and the strongest pipeline in our almost 40-year history, Gilead is entering 2026 in a position of strength.”
Against that backdrop, Gilead has guided for 4 commercial launches in 2026 alone, covering anito-cel in fourth-line multiple myeloma, Trodelvy in first-line metastatic triple-negative breast cancer, a daily oral bictegravir-plus-lenacapavir combination for HIV treatment, and bulevirtide in the US for chronic hepatitis D.
Yeztugo, which posted just $150 million in its partial first year, is guiding to around $800 million in full-year 2026 revenue, and Truist raised its price target to $155 ahead of Q1 results on expectations of broadly in-line performance.
Wall Street’s Take on GILD Stock
The market has treated Gilead Sciences stock as a yield-and-stability holding for years, but the data now describes a fundamentally different company, one with a launch cycle and pipeline density more consistent with a top-tier growth platform than a mature pharma dividend play.
Gilead’s normalized EPS reached $8.15 in 2025, up 76% year over year as acquired IPR&D charges from the prior year’s CymaBay acquisition rolled off, and consensus now estimates around $9 per share in 2026 and around $10 in 2027, representing roughly 5% and 13% growth respectively, even as Gilead absorbs integration costs from three simultaneous acquisitions.
With 17 buy ratings, 5 outperforms, 8 holds, and 1 no opinion across 30 covering analysts, the consensus mean target sits at $158, carrying 16% implied upside from the current price, and no analyst has assigned a sell rating to Gilead Sciences stock in any recent period captured in the TIKR data.
The target range runs from $123 on the low end to $180 on the high end, a spread that maps onto two distinct scenarios: one where Yeztugo sustains strong adoption and anito-cel captures meaningful share in the $3.5 billion fourth-line multiple myeloma market, and one where acquisition debt and competitive headwinds limit near-term EPS expansion.
Priced at around 16x forward normalized EPS with an EPS growth trajectory of roughly 5% to 13% annually through 2027, Gilead Sciences stock appears undervalued against a pipeline inflection that includes up to 10 commercial launches through 2027, a Biktarvy patent runway extending to 2036, and free cash flow set to grow around 33% in 2026 as prior-year working capital headwinds reverse.
CFO Andrew Dickinson told investors at the Barclays Healthcare Conference that the CAR-T multiple myeloma market is “greater than $20 billion” and that the Street had been projecting peak anito-cel sales of $2 billion to $2.5 billion against a comparable approved BCMA therapy projecting $6.5 billion, a gap Dickinson described as representing a fundamental misread of the asset’s potential.
The primary risk is execution complexity: three deals closing simultaneously in Q2 2026 introduce integration demands across cell therapy, autoimmune biology, and ADC chemistry, and any meaningful Yeztugo persistence shortfall below the injectable HIV prevention benchmark of roughly 50% refill rates would put the $800 million full-year guide at risk.
Yeztugo’s Q2 2026 revenue, reported when Gilead releases first quarter results on May 7, is the specific number to watch: that quarter will capture the first meaningful cohort of patients returning for their second injection and confirm whether the launch is building at the durable pace management has guided.
What Does the Valuation Model Say?
TIKR’s model assigns Gilead Sciences a mid-case price target of around $164, anchored to an EPS CAGR of around 8% through the forecast period and a net income margin expanding toward around 42%, assumptions directly supported by the Biktarvy LOE runway extending to 2036, the Yeztugo ramp from $150 million in 2025 toward a projected $800 million in 2026, and anito-cel’s impending launch in a $3.5 billion market that Gilead’s own management believes has been significantly undervalued by the Street.
With an EPS CAGR of around 8%, a P/E multiple contracting at around 3% annually as earnings grow faster than the stock, and free cash flow margins expanding from 32% to over 40% by the late 2020s, Gilead Sciences stock appears undervalued: the mid-case model implies a total return of around 20% from current levels, and even the low-case scenario projects the stock at around $178 by 2030.
The Investment Hinges on Whether Three Simultaneous Acquisitions Accelerate the Growth Cycle or Temporarily Obscure It
Gilead deployed over $16 billion in three deals over fewer than 60 days, and the question is not whether the science is credible (the data on anito-cel, TUB-040, and gamgertamig all argue it is) but whether the EPS accretion timeline and commercial execution match what the current multiple has already begun to price in.
Bull Case
- Yeztugo reaches the guided $800 million in 2026, validates the injectable PrEP market expansion thesis, and builds toward Johanna Mercier’s stated goal of 1 million-plus US HIV prevention users by the mid-2030s, with a potential once-yearly formulation (PURPOSE 365, expected data 2027, potential launch 2028) extending the addressable market further
- Anito-cel launches in H2 2026 with Kite’s 99% manufacturing reliability and 16-day turnaround time, differentiating on safety (zero delayed neurotoxicities or enterocolitis in iMMagine-1 versus roughly 10% neurotoxicity incidence in a competing BCMA CAR-T), and iMMagine-3 enrollment in second-line multiple myeloma positions a 2027 approval that unlocks the $20 billion-plus addressable opportunity
- Trodelvy receives FDA approval in first-line metastatic TNBC in H2 2026, doubling the addressable patient population from around 5,000 to around 10,000 with duration of treatment expanding from 4 to 5 months in second line to roughly 9 to 10 months in first line, while EVOKE-03 in PD-L1 high non-small cell lung cancer offers a high-volume indication readout in 2026
- Free cash flow growing around 33% to roughly $12.6 billion in 2026 enables management to service new acquisition debt, maintain the dividend, and continue share repurchases while integrating three deals simultaneously
Bear Case
- Yeztugo’s injection logistics in an oral-dominated HIV prevention market create a structural adoption ceiling: account-by-account pull-through in specialty pharmacy channels is inherently slower than filling a prescription, and refill rates below the injectable HIV prevention benchmark of roughly 50% in the first returning-patient cohort would require a revision to the $800 million full-year guide
- Three deals closing in Q2 2026 stretch management bandwidth across cell therapy manufacturing, autoimmune Phase Ib dose selection for gamgertamig, and ADC platform integration simultaneously, and Arcellx is management’s own guidance modestly dilutive to non-GAAP EPS through 2027 while Tubulis adds roughly $5 billion in new long-term debt
- The April 20 discontinuation of the Phase III STAR-121 study with Arcus Biosciences due to futility is a timely reminder that Gilead’s oncology pipeline carries meaningful binary risk, and a negative Phase III outcome in any 2026 pivotal readout across Trodelvy, anito-cel, or Livdelzi would materially reset the forward revenue narrative
Should You Invest in Gilead Sciences, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up GILD stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Gilead Sciences, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze GILD stock on TIKR for Free →
